Halberd Corporation Files VITA-SHIELD-MAX(TM) Trademark for Immunity Boosting Nutraceutical
Halberd Corporation (OTC PINK:HALB) has filed for trademark protection for VITA-SHIELD-MAX, a proprietary blend of nutraceuticals aimed at enhancing immunity and overall health. CEO William A. Hartman expressed optimism about the product's launch, expected in Q2 2021, emphasizing its role in boosting nutrient levels to combat health issues. The company assures compliance with OTC Market standards, holding exclusive rights to multiple COVID-19 treatment patents. However, the ongoing pandemic's impact on operations remains uncertain.
- Trademark filed for VITA-SHIELD-MAX, indicating progress in product development.
- Product launch planned for Q2 2021 suggests potential for future revenue.
- Exclusive rights to several COVID-19 treatment patents enhance competitive positioning.
- Uncertainty regarding the pandemic's impact on operational continuity and financial performance.
JACKSON CENTER, PA / ACCESSWIRE / March 11, 2021 / Halberd Corporation (OTC PINK:HALB) has filed for trademark protection for the name VITA-SHIELD-MAXTM for its proprietary blend of over-the-counter nutraceuticals designed to boost the body's immunity and generally enhance health.
William A. Hartman, Chairman, President & CEO of Halberd Corp., stated, "We are pleased to be able to complete this next step in producing and marketing our proprietary blend of ingredients to help boost immunity and general health. We think the name and planned packaging portrays the product - to help the body shield itself against various maladies which may be attributable to insufficient nutrient levels, and thus boost general health and immunity. We plan to have the product in distinctive packaging on the market in the second quarter of this year."
To get the latest news on Halberd's exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)
For more information, please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC
About Halberd Corporation.
Halberd Corporation. (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Halberd's Articles of Incorporation prohibit the company from issuance of convertible debt which would result in dilution. See the company's Articles of Incorporation here.
The company holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: "Method for Treating and Curing Covid-19 Infection;" "Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;" "Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus," "Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans," "Nasal Spray to Prevent the Transmission of Covid-19," "Method For Treating And Curing Covid-19 Infection By Utilizing Radiofrequency Extracorporeally To Eradicate The Virus," and "Medication For The Reduction Of Morbidity And Mortality In Persons Infected By Sars-Cov-2 (Covid-19 Virus)." Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.
Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.
The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.
The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.
We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.
SOURCE: Halberd Corporation
View source version on accesswire.com:
https://www.accesswire.com/634885/Halberd-Corporation-Files-VITA-SHIELD-MAXTM-Trademark-for-Immunity-Boosting-Nutraceutical
FAQ
What is the purpose of Halberd Corporation's VITA-SHIELD-MAX?
When is Halberd Corporation planning to launch VITA-SHIELD-MAX?
What patents does Halberd Corporation hold related to COVID-19?
What stock symbol represents Halberd Corporation?
What compliance status does Halberd Corporation hold?
